# OrigAMI-5: HCP commentary report

> 327 verified statements (289 from clinicians verified by NPI or staff page) from 23 commentary sources · 11 findings · updated Oct 31, 2026

## Report

- Trial: A Phase 3, Randomized, Open-Label, Multicenter Study of Amivantamab in Addition to Carboplatin and Pembrolizumab, Compared to Standard of Care Platinum and Pembrolizumab and 5-FU, in Participants With Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
- NCT ID: NCT07276399
- Registry: https://clinicaltrials.gov/study/NCT07276399
- Sponsor: Janssen Research & Development, LLC
- Phase: Phase 3
- Status: Recruiting
- Drugs tested: amivantamab plus pembrolizumab
- Indication: treatment-naïve recurrent/metastatic head and neck squamous cell carcinoma
- Version: v1.0.0, edition 1
- Accepted: 2026-10-31
- Last checked: 2026-10-31
- Release hash: c224a47ee6fc216fea2aa9a6a59b77693cb0507dfa452829f1cddc1ad8a5fe4e

## Counts

- HCP commentary sources screened: 36
- Sources cited by verified statements: 23
- Verified statements: 327
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 289
- Findings: 11
- Named people in screened sources (unnamed speakers and accounts not counted): 16
- Voices cited: 16
- Cited voices identity-verified: 11
- Organisational or shared accounts (not counted as people): 3

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

OrigAMI-5 tests whether amivantamab, carboplatin and pembrolizumab improve response and survival versus platinum, 5-FU and pembrolizumab in first-line HPV-negative recurrent/metastatic head and neck squamous cell cancer. Commentary includes podcasts and YouTube discussions with medical oncologists and nurse practitioners, alongside X posts. The discussion turns on conditional preferences for OrigAMI-5 enrollment and whether amivantamab has a first-line role, which remains unresolved despite enthusiasm for OrigAMI-04 activity.

## Open Medical Affairs question

Which patients need the chemotherapy-backed research option rather than monotherapy or local salvage, and what evidence and supportive care would justify changing practice?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. The chemotherapy-backed comparison is a reason to favor enrollment for symptomatic patients—not evidence of established benefit
- F2. Resectability and treatment goals remain gates before first-line systemic research
- F3. Lung-regimen VTE experience does not establish a head-and-neck anticoagulation requirement
- F4. Strong enthusiasm is grounded in OrigAMI-04 activity, while the first-line randomized question remains unanswered
- F5. The existing alternatives include justified reasons to omit, retain or change chemotherapy
- F6. HPV-negative unmet need and EGFR/MET biology support development, not validated agent matching
- F7. Subcutaneous delivery is attractive, but reaction risk, visit burden and combination experience remain qualified
- F8. Proactive toxicity care is central to feasibility, with limits on extrapolation and monitoring generalization
- F9. Sequencing preferences are conditional, while reported later-line access is distinct from approval
- F10. Trial suitability includes patient willingness, practical access and sustained multidisciplinary support
- F_RM_STANDARD_CARE_CONTEXT. Routine-care alternatives qualify interest in the first-line trial

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding.

| Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| F1 | 18 | 15 | 7 | 4 | recorded | 3 |
| F2 | 19 | 15 | 3 | 3 | recorded | 3 |
| F3 | 7 | 8 | 3 | 3 | recorded | 3 |
| F4 | 33 | 26 | 14 | 9 | recorded | 6 |
| F5 | 27 | 19 | 7 | 5 | recorded | 4 |
| F6 | 31 | 28 | 10 | 7 | recorded | 4 |
| F7 | 27 | 20 | 9 | 5 | recorded | 4 |
| F8 | 20 | 10 | 5 | 4 | recorded | 4 |
| F9 | 16 | 12 | 6 | 5 | recorded | 5 |
| F10 | 25 | 12 | 5 | 5 | recorded | 3 |
| F_RM_STANDARD_CARE_CONTEXT | 3 | 3 | 1 | 2 | none recorded | 2 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Passages supporting | Passages giving context | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 9 | 1 | 0 | 3 | 5 | 21 | 1 | 7 podcasts and video | yes |
| F2 | 10 | 2 | 3 | 1 | 3 | 20 | 3 | 3 podcasts and video | yes |
| F3 | 3 | 1 | 2 | 0 | 1 | 9 | 2 | 3 podcasts and video | yes |
| F4 | 14 | 3 | 1 | 6 | 9 | 35 | 7 | 3 posts and articles, 11 podcasts and video | yes |
| F5 | 12 | 0 | 4 | 2 | 9 | 32 | 2 | 7 podcasts and video | yes |
| F6 | 21 | 0 | 2 | 1 | 7 | 33 | 4 | 10 podcasts and video | yes |
| F7 | 9 | 0 | 4 | 9 | 5 | 29 | 2 | 9 podcasts and video | yes |
| F8 | 16 | 0 | 2 | 1 | 1 | 21 | 1 | 5 podcasts and video | yes |
| F9 | 8 | 2 | 3 | 0 | 3 | 18 | 2 | 6 podcasts and video | yes |
| F10 | 15 | 3 | 4 | 0 | 3 | 27 | 0 | 5 podcasts and video | yes |
| F_RM_STANDARD_CARE_CONTEXT | 2 | 0 | 1 | 0 | 0 | 3 | 0 | 1 podcast or video | yes |

### Trial dimensions

- Primary endpoint: Overall Survival (OS): F1 (1 shared claims), F4 (1 shared claims), F6 (1 shared claims), F9 (1 shared claims)
- Primary endpoint: Objective Response Rate (ORR) Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR): F1 (3 shared claims), F5 (1 shared claims), F9 (1 shared claims)
- Secondary endpoints: F1 (1 shared claims), F4 (6 shared claims), F8 (1 shared claims)
- Population and setting: F1 (5 shared claims), F4 (1 shared claims), F6 (5 shared claims), F9 (1 shared claims)
- The comparison: F1 (9 shared claims), F5 (4 shared claims)
- Safety and tolerability: F1 (1 shared claims), F3 (5 shared claims), F7 (16 shared claims), F8 (17 shared claims)
- Design and conduct: F1 (1 shared claims), F3 (1 shared claims), F4 (5 shared claims), F6 (2 shared claims), F7 (1 shared claims), F8 (1 shared claims), F9 (2 shared claims)

## Sample findings

Paraphrased; the full report links each statement to its source.

### F4. Strong enthusiasm is grounded in OrigAMI-04 activity, while the first-line randomized question remains unanswered

A YouTube panel addresses how to interpret earlier amivantamab response findings and what evidence is needed to assess its role in first-line treatment.

Source: YouTube video, 2026-06-02.

### F1. The chemotherapy-backed comparison is a reason to favor enrollment for symptomatic patients—not evidence of established benefit

A physician in a YouTube discussion addresses how trial comparators enter enrollment decisions for symptomatic patients considering first-line treatment.

Source: YouTube video, 2026-02-19.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 11 | Titles free |
| Detailed analysis | 11 sections | Paid |
| Verified statements with short source quotes and links | 327 | Paid |
| Trial aspects mapped | 14 | Free |
| Sources with links | 23 | Counts free |
| Speaker attribution for cited voices | 16 | Paid |

## Trial aspects

14 discussed · 0 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Overall Survival (OS) | discussed | 5 | 3 |
| Primary endpoint: Objective Response Rate (ORR) Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) | discussed | 5 | 3 |
| Secondary endpoints | discussed | 8 | 5 |
| Population and setting | discussed | 11 | 9 |
| The comparison | discussed | 12 | 6 |
| Safety and tolerability | discussed | 34 | 7 |
| Design and conduct | discussed | 10 | 8 |
| Resectability, local salvage and goals of treatment | discussed | 17 | 2 |
| Current alternatives and reasons to avoid or modify chemotherapy | discussed | 20 | 6 |
| OrigAMI-04 activity and the need for confirmation | discussed | 25 | 12 |
| Biological rationale, work-up and predictive biomarker needs | discussed | 21 | 8 |
| Administration schedules, monitoring and practical burden | discussed | 10 | 6 |
| Sequencing, regulatory expectations and reported access | discussed | 10 | 4 |
| Patient willingness, logistics and multidisciplinary support | discussed | 19 | 5 |

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| X threads | 18 | 8 |
| YouTube | 9 | 9 |
| Podcasts | 4 | 4 |
| Bluesky threads | 4 | 1 |
| X videos | 1 | 1 |

- Screened window: 2025-10-19 to 2026-10-25
- Cited window: 2025-10-19 to 2026-10-25
- Retrieved: 2026-10-31

Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Phase 3, Randomized, Open-Label, Multicenter Study of Amivantamab in Addition to Carboplatin and Pembrolizumab, Compared to Standard of Care Platinum and Pembrolizumab and 5-FU, in Participants With Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
- Registry: NCT07276399 (https://clinicaltrials.gov/study/NCT07276399)
- Study IDs: 61186372HNC3001 · 2025-521917-24-00 (EUCT number)
- Sponsor: Janssen Research & Development, LLC
- Design: Phase 3 · interventional, randomized, parallel, phase3
- Status: Recruiting
- Enrollment: 500 (estimated)
- Start: 2025-12-03 (actual)
- Primary completion: 2029-06-18 (estimated)
- Primary endpoint: Overall Survival (OS) (Up to approximately 3 years 7 months)
- Primary endpoint: Objective Response Rate (ORR) Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (Up to approximately 3 years 7 months)
- Intervention: Amivantamab (biological)
- Intervention: Pembrolizumab (biological)
- Intervention: Carboplatin (drug)
- Intervention: 5-Flurouracil (drug)
- Intervention: Cisplatin (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- Not yet captured in this edition: a view on limitations of target-lesion-based response assessment in recurrent/metastatic head and neck cancer.
- Not yet captured in this edition: a remark on the trial’s launch, untreated HPV-unrelated recurrent/metastatic population and randomized treatment comparison.
- Not yet captured in this edition: a view on patient selection for first-line treatment of recurrent head and neck cancer after prior definitive therapy.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 178 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
- The sources reviewed for this edition are not a representative sample of HCP opinion. Educational sessions can appear in multiple formats, and posts may relay the same underlying remarks.
- Coverage favored trial identifiers and names. Discussions of the same clinical decision without those references, including older discussions, may be underrepresented, and some potentially relevant passages were not fully assessed.
- No full protocol or exact-trial results publication was available for this report. The drug's regulatory context was not comprehensively assessed, so reported eligibility, dosing, monitoring and approval expectations are not confirmed protocol or regulatory rules.
- Most efficacy enthusiasm concerns OrigAMI-04 or other early clinical experience, often single-arm, small and compared with historical expectations. It cannot establish OrigAMI-5 comparative benefit or harm.
- Source publication dates can differ from session or presentation dates. Differences between dated accounts do not by themselves demonstrate a change of mind.
- Some passages cannot be assigned to a named speaker. Program titles, participant lists and professional profiles do not resolve who spoke those passages.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- PD-L1 eligibility accounts differ, and one combination-experience assertion sits alongside discussion of an amivantamab–paclitaxel cohort. These statements are preserved as expressed rather than silently reconciled.
- A compressed complete-response comparison leaves the ownership of a 15% figure unclear, and reported reaction rates and observation practices concern different cohorts or settings.
- Detailed strategies for populations outside the HPV-negative/HPV-unrelated first-line decision are not developed in this narrative; their statements remain available separately.
- The forthcoming frontline cohort-5 triplet account and parts of the alternative-bispecific efficacy and response-durability discussion are not fully covered here. Comparisons among these options therefore remain incomplete.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, accepted 2026-10-31: current edition

Last checked for new commentary 2026-10-31. No corrections. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch.

## Offer

- Size: Deep (327 verified statements)
- Current edition: $1,950. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $3,400
- 6 months of weekly updates: $4,900
- 12 months of weekly updates: $6,800
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (11 now), at most $1,950; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/origami-5-nct07276399
- Agents: POST https://www.erudio.com/api/orders with {"report": "origami-5-nct07276399", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=origami-5-07276399

## Cite

Erudio Health. OrigAMI-5 (NCT07276399): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 31, 2026. https://www.erudio.com/reports/origami-5-nct07276399

## Machine access

- JSON: https://www.erudio.com/reports/origami-5-nct07276399.json
- Markdown: https://www.erudio.com/reports/origami-5-nct07276399.md
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "origami-5-07276399"}`